Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, Cameron Wellard, Krystal Bergin, Bradley Augustson, Hilary Blacklock, Simon J Harrison, Noemi Horvath, Tracy King, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Erica M Wood, Andrew Spencer
Clinical Lymphoma Myeloma and Leukemia | CIG MEDIA GROUP, LP | Published : 2019
BACKGROUND: Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite improved survival with newer therapies. PATIENTS AND METHODS: We evaluated baseline characteristics, treatment, and outcomes of newly diagnosed MM patients with RI at diagnosis in the Australia and New Zealand Myeloma and Related Diseases Registry over 5 years to April 2018; we compared patients with RI (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2) with those with eGFR ≥60. In autologous stem cell transplantation (ASCT) analyses, patients aged 70 years and younger and ≥1 year from diagnosis were included. RESULTS: Overall, 36% of patients with ne..View full abstract
The authors thank the patients, hospitals, clinicians, and research staff at participating institutions for their support of the MRDR. This research did not receive any specific grant from funding agencies in the public, commercial, or not for profit sectors, however, the ANZ MRDR has received funding from Amgen, Bristol-Myers Squibb, Celgene, Gilead, Janssen, Novartis, and Takeda.